Why Summit Therapeutics Inc. (SMMT) Stock Fell 6.3% on Oct 26, 2026
The clearest new catalyst: Positive Phase III data from partner Akeso.
Why did SMMT stock fall?
Summit Therapeutics fell 6.3% on October 26, 2026, despite partner Akeso's announcement of positive Phase III HARMONi-GI1 results for ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The decline suggests investors are discounting execution risk, regulatory uncertainty, or broader sector headwinds despite the clinical win.
- Positive Phase III data from partner Akeso: Akeso announced that ivonescimab plus chemotherapy achieved overall survival superiority over durvalumab plus chemotherapy in the HARMONi-GI1 trial for first-line advanced biliary tract cancer, a significant clinical milestone for the partnership.
- Investor skepticism on execution and regulatory pathway: Despite the clinical success, the stock declined, indicating the market may be pricing in concerns about development timelines, regulatory approval uncertainty, or commercialization challenges.
Initial detection
BestStocks first flagged SMMT intraday on Oct 26, 2026; this analysis was finalized after the close using the confirmed −6.3% session move and additional catalyst research.
Show the initial intraday note
Summit Therapeutics declined 5.56% to $14.61 despite partner Akeso announcing positive Phase III HARMONi-GI1 results showing ivonescimab plus chemotherapy achieved overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer treatment (Business Wire, 2026-10-25). The stock fell despite the clinical win, suggesting investors may be pricing in execution risk, regulatory pathway uncertainty, or broader market headwinds. Volume of 2.0M shares trades at 0.81x historical average for this time of session — within normal range.
What to watch next: Summit Therapeutics earnings call on 2026-11-11 (date pending confirmation); management guidance on ivonescimab development timeline, regulatory strategy, and royalty assumptions from Akeso partnership.
Other developments that session
Partner Akeso's ivonescimab plus chemotherapy showed superior overall survival versus durvalumab in advanced biliary tract cancer.
Frequently asked questions
Why did Summit Therapeutics Inc. (SMMT) stock fall on Oct 26, 2026?
Summit Therapeutics fell 6.3% on October 26, 2026, despite partner Akeso's announcement of positive Phase III HARMONi-GI1 results for ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The decline suggests investors are discounting execution risk, regulatory uncertainty, or broader sector headwinds despite the clinical win.
How much did SMMT stock fall on Oct 26, 2026?
SMMT fell 6.3% during the Oct 26, 2026 trading session.
What were the main drivers behind SMMT's move?
Positive Phase III data from partner Akeso; Investor skepticism on execution and regulatory pathway.